Difference between revisions of "He JT, et al. Mol. Cell. Proteom. (2012) cited as Ref 679 in DOI: 10.1038/s41392-020-0110-5 (Q9942)"
Jump to navigation
Jump to search
(Created claim: Volume (P103): 11, #quickstatements; #temporary_batch_1590009084631) |
(Created claim: title (P93): CD90 is identified as a candidate marker for cancer stem cells in primary high-grade gliomas using tissue microarrays, #quickstatements; #temporary_batch_1590010982689) |
||
| Property / title | |||
| + | CD90 is identified as a candidate marker for cancer stem cells in primary high-grade gliomas using tissue microarrays (English) | ||
| Property / title: CD90 is identified as a candidate marker for cancer stem cells in primary high-grade gliomas using tissue microarrays (English) / rank | |||
| + | Normal rank | ||
Revision as of 22:06, 20 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
He JT, et al. Mol. Cell. Proteom. (2012) cited as Ref 679 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
He JT
0 references
2012
0 references
Mol. Cell. Proteom.
0 references
11
0 references
CD90 is identified as a candidate marker for cancer stem cells in primary high-grade gliomas using tissue microarrays (English)
0 references
